Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

Abstract Background Biomarker assessments for nivolumab monotherapy efficacy in previously treated patients with non‐small cell lung cancer (NSCLC) remain unclear. We evaluated whether body mass index (BMI) and Glasgow prognostic score (GPS) are useful for assessing the efficacy of nivolumab alone a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2022-05-01
Edice:	Thoracic Cancer
Témata:	body mass index carcinoma glasgow prognostic score nivolumab non‐small‐cell lung performance status
On-line přístup:	https://doi.org/10.1111/1759-7714.14417
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!